PDF herunterladen
Horm Metab Res 2020; 52(06): 373-378
DOI: 10.1055/a-1141-3526
Review

Developments in Primary Aldosteronism Subtyping Using Steroid Profiling

Taweesak Wannachalee 
1   Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, USA
2   Division of Endocrinology and Metabolism, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Adina F. Turcu 
1   Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, USA
› Institutsangaben Funding: AFT was supported by grants1K08DK109116 from the NIDDK and 2019087 from the Doris Duke Charitable Foundation.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Adrenal venous sampling is the standard of care for identifying patients with unilateral primary aldosteronism, which is often caused by an aldosterone producing adenoma and can be cured with surgery. The numerous limitations of adrenal venous sampling, including its high cost, scarce availability, technical challenges, and lack of standardized protocols, have driven efforts to develop alternative, non-invasive tools for the diagnosis of aldosterone producing adenomas. Seminal discoveries regarding the pathogenesis of aldosterone producing adenomas made over the past decade have leveraged hypotheses-driven research of steroid phenotypes characteristic of various aldosterone producing adenomas. In parallel, the expanding availability of mass spectrometry has enabled the simultaneous quantitation of many steroids in single assays from small volume biosamples. Steroid profiling has contributed to our evolving understanding about the pathophysiology of primary aldosteronism and its subtypes. Herein, we review the current state of knowledge regarding the application of multi-steroid panels in assisting with primary aldosteronism subtyping.

Key words

primary aldosteronism - adrenal vein sampling - steroids - adrenal - aldosterone


Publikationsverlauf

Eingereicht: 28. Dezember 2019

Angenommen: 09. März 2020

Artikel online veröffentlicht:
24. April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies−a review of the current literature. Horm Metab Res 2012; 44: 157-162
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
    PubMedGoogle Scholar
  • 3 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
    CrossrefPubMedGoogle Scholar
  • 4 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
    CrossrefPubMedGoogle Scholar
  • 5 Douma S, Petidis K, Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet 2008; 371: 1921-1926
    CrossrefPubMedGoogle Scholar
  • 6 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
    CrossrefPubMedGoogle Scholar
  • 7 Hundemer GL, Curhan GC, Yozamp N. et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 2018; 3: 768-774
    CrossrefPubMedGoogle Scholar
  • 8 Mulatero P, Monticone S, Bertello C. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833
    CrossrefPubMedGoogle Scholar
  • 9 Fallo F, Veglio F, Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
    CrossrefPubMedGoogle Scholar
  • 10 Hundemer GL, Curhan GC, Yozamp N. et al. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 2018; 72: 658-666
    CrossrefPubMedGoogle Scholar
  • 11 Rossi GP, Cesari M, Cuspidi C. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-69
    CrossrefPubMedGoogle Scholar
  • 12 Iwakura Y, Morimoto R, Kudo M. et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: Renal outcome of 213 cases. J Clin Endocrinol Metab 2014; 99: 1593-1598
    CrossrefPubMedGoogle Scholar
  • 13 Williams TA, Lenders JWM, Mulatero P. et al. Primary aldosteronism surgery outcome i. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
    CrossrefPubMedGoogle Scholar
  • 14 Nanba AT, Nanba K, Byrd JB. et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol 2017; 87: 665-672
    CrossrefPubMedGoogle Scholar
  • 15 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34
    CrossrefPubMedGoogle Scholar
  • 16 Mantero F, Terzolo M, Arnaldi G. et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
    PubMedGoogle Scholar
  • 17 Williams TA, Burrello J, Sechi LA. et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018; 72: 641-649
    CrossrefPubMedGoogle Scholar
  • 18 Lim V, Guo Q, Grant CS. et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99: 2712-2719
    CrossrefPubMedGoogle Scholar
  • 19 Young WF, Stanson AW, Thompson GB. et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-1235
    CrossrefPubMedGoogle Scholar
  • 20 Kempers MJ, Lenders JW, van Outheusden L. et al. Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151: 329-337
    CrossrefPubMedGoogle Scholar
  • 21 Young WF. Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. J Intern Med 2019; 285: 126-148
    CrossrefPubMedGoogle Scholar
  • 22 Rossi GP, Auchus RJ, Brown M. et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63: 151-160
    CrossrefPubMedGoogle Scholar
  • 23 Monticone S, Viola A, Rossato D. et al. Adrenal vein sampling in primary aldosteronism: Towards a standardised protocol. Lancet Diabetes Endocrinol 2015; 3: 296-303
    CrossrefPubMedGoogle Scholar
  • 24 Laurent I, Astere M, Zheng F. et al. Adrenal venous sampling with or without adrenocorticotropic hormone stimulation: A meta-analysis. J Clin Endocrinol Metab 2019; 104: 1060-1068
    CrossrefPubMedGoogle Scholar
  • 25 Choi M, Scholl UI, Yue P. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
    CrossrefPubMedGoogle Scholar
  • 26 Azizan EA, Poulsen H, Tuluc P. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
    CrossrefPubMedGoogle Scholar
  • 27 Scholl UI, Goh G, Stolting G. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45: 1050-1054
    CrossrefPubMedGoogle Scholar
  • 28 Beuschlein F, Boulkroun S, Osswald A. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444
    CrossrefPubMedGoogle Scholar
  • 29 Nanba K, Omata K, Gomez-Sanchez CE. et al. Genetic characteristics of aldosterone-producing adenomas in blacks. Hypertension 2019; 73: 885-892
    CrossrefPubMedGoogle Scholar
  • 30 Nanba K, Omata K, Else T. et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab 2018; 103: 3869-3876
    CrossrefPubMedGoogle Scholar
  • 31 Monticone S, Castellano I, Versace K. et al. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology 2015; 411: 146-154
    CrossrefPubMedGoogle Scholar
  • 32 Lenzini L, Rossitto G, Maiolino G. et al. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab 2015; 100: E1089-E1095
    CrossrefPubMedGoogle Scholar
  • 33 Yamazaki Y, Omata K, Tezuka Y. et al. Tumor cell subtypes based on the intracellular hormonal activity in KCNJ5-mutated aldosterone-producing adenoma. Hypertension 2018; 72: 632-640
    CrossrefPubMedGoogle Scholar
  • 34 Ono Y, Yamazaki Y, Omata K et al. Histological characterization of aldosterone-producing adrenocortical adenomas with different somatic mutations. J Clin Endocrinol Metab 2020; 105: pii: dgz235, DOI: 10.1210/clinem/dgz235
    PubMed
  • 35 Kitamoto T, Suematsu S, Yamazaki Y. et al. Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations. J Clin Endocrinol Metab 2016; 101: 494-503
    CrossrefPubMedGoogle Scholar
  • 36 Inoue K, Yamazaki Y, Kitamoto T. et al. Aldosterone suppression by dexamethasone in patients with KCNJ5-mutated aldosterone-producing adenoma. J Clin Endocrinol Metab 2018; 103: 3477-3485
    CrossrefPubMedGoogle Scholar
  • 37 Ono Y, Nakamura Y, Maekawa T. et al. Different expression of 11beta-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas. Hypertension 2014; 64: 438-444
    CrossrefPubMedGoogle Scholar
  • 38 Tezuka Y, Yamazaki Y, Kitada M. et al. 18-Oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status. Hypertension 2019; 73: 1283-1290
    CrossrefPubMedGoogle Scholar
  • 39 Nakamura Y, Kitada M, Satoh F. et al. Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17. Mol Cell Endocrinol 2016; 422: 57-63
    CrossrefPubMedGoogle Scholar
  • 40 Williams TA, Peitzsch M, Dietz AS. et al. Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension 2016; 67: 139-145
    CrossrefPubMedGoogle Scholar
  • 41 Nanba K, Blinder AR, Rege J. et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension 2020; 75: 645-649
    CrossrefPubMedGoogle Scholar
  • 42 Wannachalee T, Zhao L, Nanba K. et al. Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling. J Clin Endocrinol Metab 2019; 104: 5867-5876
    CrossrefPubMedGoogle Scholar
  • 43 Stowasser M, Bachmann AW, Tunny TJ. et al. Production of 18-oxo-cortisol in subtypes of primary aldosteronism. Clin Exp Pharmacol Physiol 1996; 23: 591-593
    CrossrefPubMedGoogle Scholar
  • 44 Mosso L, Gomez-Sanchez CE, Foecking MF. et al. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001; 38: 688-691
    CrossrefPubMedGoogle Scholar
  • 45 Gordon RD, Hamlet SM, Tunny TJ. et al. Distinguishing aldosterone-producing adenoma from other forms of hyperaldosteronism and lateralizing the tumour pre-operatively. Clin Exp Pharmacol Physiol 1986; 13: 325-328
    CrossrefPubMedGoogle Scholar
  • 46 Chu MD, Ulick S. Isolation and identification of 18-hydroxycortisol from the urine of patients with primary aldosteronism. J Biol Chem 1982; 257: 2218-2224
    CrossrefPubMedGoogle Scholar
  • 47 Ulick S, Blumenfeld JD, Atlas SA. et al. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993; 76: 873-878
    PubMedGoogle Scholar
  • 48 Hamlet SM, Gordon RD, Gomez-Sanchez CE. et al. Adrenal transitional zone steroids, 18-oxo and 18-hydroxycortisol, useful in the diagnosis of primary aldosteronism, are ACTH-dependent. Clin Exp Pharmacol Physiol 1988; 15: 317-322
    CrossrefPubMedGoogle Scholar
  • 49 Gomez-Sanchez CE, Montgomery M, Ganguly A. et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism. J Clin Endocrinol Metab 1984; 59: 1022-1024
    CrossrefPubMedGoogle Scholar
  • 50 Satoh F, Morimoto R, Ono Y. et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 2015; 65: 1096-1102
    CrossrefPubMedGoogle Scholar
  • 51 Eisenhofer G, Dekkers T, Peitzsch M. et al. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem 2016; 62: 514-524
    CrossrefPubMedGoogle Scholar
  • 52 Zheng FF, Zhu LM, Nie AF. et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension 2015; 65: 622-628
    CrossrefPubMedGoogle Scholar
  • 53 Taguchi R, Yamada M, Nakajima Y. et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-1319
    CrossrefPubMedGoogle Scholar
  • 54 Akerstrom T, Crona J, Delgado Verdugo A. et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PloS one 2012; 7: e41926
    CrossrefPubMedGoogle Scholar
  • 55 Boulkroun S, Beuschlein F, Rossi GP. et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-598
    CrossrefPubMedGoogle Scholar
  • 56 Azizan EA, Murthy M, Stowasser M. et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59: 587-591
    CrossrefPubMedGoogle Scholar
  • 57 Monticone S, Hattangady NG, Nishimoto K. et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 97: E1567-E1572
    CrossrefPubMedGoogle Scholar
  • 58 Azizan EA, Lam BY, Newhouse SJ. et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97: E819-E829
    CrossrefPubMedGoogle Scholar
  • 59 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
    CrossrefPubMedGoogle Scholar
  • 60 Arlt W, Lang K, Sitch A et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. https://www.ncbi.nlm.nih.gov/pubmed/28422753. JCI Insight 2017; 2: pii: 93136. doi: 10.1172/jci.insight.93136. eCollection 2017 Apr 20
    PubMed
  • 61 El Ghorayeb N, Mazzuco TL, Bourdeau I. et al. Basal and Post-ACTH aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism. J Clin Endocrinol Metab 2016; 101: 1826-1835
    CrossrefPubMedGoogle Scholar
  • 62 Takeda M, Yamamoto K, Akasaka H. et al. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab 2018; 103: 3620-3629
    CrossrefPubMedGoogle Scholar
  • 63 Wolley MJ, Gordon RD, Ahmed AH. et al. Does contralateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study. J Clin Endocrinol Metab 2015; 100: 1477-1484
    CrossrefPubMedGoogle Scholar
  • 64 Tagawa M, Ghosn M, Wachtel H. et al. Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism. J Hum Hypertens 2017; 31: 444-449
    CrossrefPubMedGoogle Scholar
  • 65 Turcu AF, Wannachalee T, Tsodikov A. et al. Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping. Hypertension 2020; 75: 183-192
    CrossrefPubMedGoogle Scholar